Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.
Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 31, 2021 | Convertable Note | €14M | 2 | Luminous Ventures The Future Fund | — | Detail |
Mar 20, 2021 | Series A | €11.67M | 1 | — | — | Detail |
Feb 13, 2017 | Series Unknown | $8M | 1 | BXR Partners LLP | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Luminous Ventures | Yes | Convertable Note |
The Future Fund | Yes | Convertable Note |
BXR Partners LLP | Yes | Series Unknown |
Outsized Ventures | — | Series A |